NCT07611188

Brief Summary

Current international guidelines recommend that patients with a heart pump (left ventricular assist device, LVAD) participate in supervised exercise cardiac rehabilitation programs. However, not all patients with a heart pump are able to attend to a supervised program on a daily basis. The goal of this clinical trial is to determine whether a home-based exercise program helps patients with a heart pump improve their exercise capacity and quality of life, guided by telemedicine tools including a mobile app, smartwatch, and remote medical checkups. The study will also provide information about the safety of this program by monitoring for any issues or symptoms during home activity. The trial aims to answer the following questions:

  • Does a 12-week remote exercise program improve patients' exercise capacity? This will be measured using the 6-minute walk test and a cardiopulmonary exercise test.
  • Is it safe for patients to follow this exercise plan at home while being monitored through a mobile app and smartwatch?
  • Does the program improve quality of life and reduce feelings of anxiety or depression? This will be assessed using widely validated questionnaires, such as the Kansas City Cardiomyopathy Questionnaire. Researchers will compare the remote exercise program to standard care, which usually does not include exercise for patients who are unable to attend the hospital daily. Participants will:
  • Join the study voluntarily after signing a consent form.
  • Be randomly assigned, with a 50% chance of being in either the exercise group (following a structured plan with a mobile app) or the usual care group (receiving general written advice), to see which approach works best for recovery.
  • Follow a 12-week home-based routine if in the exercise group, including warm-up routine, walking or cycling, respiratory exercises, and light strength training, all supported by the mobile app, smartwatch, and professional monitoring.
  • Visit the hospital three times over six months for medical checkups, including walking and exercise tests, blood analyses, and questionnaires about physical and emotional health.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
78

participants targeted

Target at P25-P50 for not_applicable heart-failure

Timeline
54mo left

Started May 2026

Longer than P75 for not_applicable heart-failure

Geographic Reach
1 country

10 active sites

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress3%
May 2026Dec 2030

First Submitted

Initial submission to the registry

March 6, 2026

Completed
2 months until next milestone

Study Start

First participant enrolled

May 1, 2026

Completed
27 days until next milestone

First Posted

Study publicly available on registry

May 28, 2026

Completed
3.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2029

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2030

Last Updated

May 28, 2026

Status Verified

May 1, 2026

Enrollment Period

3.6 years

First QC Date

March 6, 2026

Last Update Submit

May 20, 2026

Conditions

Keywords

Left Ventricular Assist DeviceAdvanced Heart FailureHeart FailureCardiac RehabilitationRemote rehabilitationTelemedicine6 minute walking testQuality of LifeCardiopulmonary Exercise TestTelerehabilitation

Outcome Measures

Primary Outcomes (1)

  • Six-Minute Walk Test (6MWT)

    Difference in walking distance (meters) in the Six-Minute Walk Test (6MWT).

    3 months

Secondary Outcomes (17)

  • Program Safety

    6 months

  • Cardiopulmonary Exercise Test (CPET): peak oxygen consumption (VO₂peak)

    3 months

  • Cardiopulmonary Exercise Test (CPET): VE/VO₂ slope

    3 months

  • Cardiopulmonary Exercise Test (CPET): oxygen consumption at the first and second ventilatory thresholds

    3 months

  • Cardiopulmonary Exercise Test (CPET): ventilatory equivalents

    3 months

  • +12 more secondary outcomes

Other Outcomes (3)

  • Program Satisfaction and Adherence

    6 months

  • Comparison of Outcomes Between Remote conditioning and Supervised Rehabilitation

    6 months

  • Evaluation of Outcomes by Sex and by the aim of LVAD

    6 months

Study Arms (2)

Remote Exercise Training Via Telemedicine

EXPERIMENTAL

Warm-up, Respiratory Training, Continuous Aerobic Exercise, and Strength Training. Remote Monitoring via Telemedicine.

Other: Remote Physical Conditioning Program (Telerehabilitation)

Control Group

OTHER

Usual care. General Exercise Recommendations (Written Instructions). No Remote Monitoring.

Other: Usual care. No Remote Monitoring.

Interventions

The program includes structured warm-up routines, respiratory training, continuous aerobic exercise, and strength training, with remote follow-up conducted via telemedicine.

Remote Exercise Training Via Telemedicine

General Exercise Recommendations (Written Instructions). No Remote Monitoring.

Control Group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Recent LVAD Implantation (\<6 months)
  • Clinical stability (defined as meeting all of the following criteria): discharge from the LVAD implantation hospitalization, absence of inotropic medication, hemoglobin \>9 g/dL, and no active infection.
  • Inability to participate in a supervised rehabilitation program (due to lack of availability, or inability because geographical reasons).

You may not qualify if:

  • Functional Inability to Perform Cardiopulmonary Exercise Testing
  • Prior Participation in a Supervised Rehabilitation Program (after the LVAD implantation)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (10)

Hospital Virgen del Rocío

Seville, Andalusia, 41013, Spain

Location

Hospital Universitario de Salamanca

Salamanca, Castille and León, 37007, Spain

Location

Hospital Clinic de Barcelona

Barcelona, Catalonia, 03036, Spain

Location

Hospital Universitari de Bellvitge

Barcelona, Catalonia, Spain

Location

Complejo Hospitalario Universitario de A Coruña

A Coruña, Galicia, 15006, Spain

Location

Complejo Hospitalario Universitario Santiago de Compostela

Santiago de Compostela, Galicia, 15706, Spain

Location

Hospital Ramon y Cajal

Madrid, Madrid, 28034, Spain

Location

Hospital Clinico San Carlos

Madrid, Madrid, 28040, Spain

Location

Hospital 12 de Octubre

Madrid, Madrid, 28041, Spain

Location

Hospital Puerta de Hierro

Majadahonda, Madrid, 28028, Spain

Location

MeSH Terms

Conditions

Heart Failure

Interventions

Telerehabilitation

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

RehabilitationAftercareContinuity of Patient CarePatient CareTherapeuticsHealth ServicesHealth Care Facilities Workforce and ServicesTelemedicineDelivery of Health CarePatient Care ManagementHealth Services Administration

Study Officials

  • Mercedes Rivas-Lasarte, MD, PhD

    Hospital Puerta de Hierro, Madrid (Spain)

    PRINCIPAL INVESTIGATOR
  • Ramon Garrido Gonzalez, MD

    Hospital Puerta de Hierro, Madrid (Spain)

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Mercedes Rivas-Lasarte, MD, PhD, Cardiologist

CONTACT

Ramon Garrido Gonzalez, MD, Cardiologist

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Multicenter, randomized, and controlled clinical trial
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Cardiologist, MD, PhD

Study Record Dates

First Submitted

March 6, 2026

First Posted

May 28, 2026

Study Start

May 1, 2026

Primary Completion (Estimated)

December 1, 2029

Study Completion (Estimated)

December 1, 2030

Last Updated

May 28, 2026

Record last verified: 2026-05

Data Sharing

IPD Sharing
Will share

Upon completion of the project and publication of the primary analysis, the data will be deposited in the Zenodo repository following appropriate anonymization procedures. The dataset will be accompanied by metadata in Zenodo including: (1) data provenance, (2) patient population characteristics, and (3) a detailed description of the study variables. Access to data stored in the internal repository for other investigators with legitimate scientific interest will be subject to approval by the Ethics Committee. This approach ensures compliance with open-access data requirements applicable to publicly funded research projects, while maintaining data within a controlled environment consistent with their nature as personal data.

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
Time Frame
Data are expected to be available beginning in January 2031, following completion of the study and publication of the primary analysis.
Access Criteria
Data will be shared with investigators who provide a methodologically sound research proposal and demonstrate legitimate scientific interest.

Locations